Extension of agreement with Accord Healthcare

24 November 2015

Clinigen Group extends exclusive clinical trial distribution agreement withAccord Healthcare for another two years

European agreement adds four new products across additional therapeutic areas taking total up to 17

Clinigen Group plc (AIM: CLIN, 'Clinigen' or the 'Group') the global pharmaceutical and services company, announces that its global leading Clinical Trial Services business (Clinigen CTS) has renewed an exclusive European Union (EU) clinical trial distribution agreement with Accord Healthcare ('Accord'), a wholly-owned marketing subsidiary of Intas Pharmaceuticals, for a further two years.

The agreement has also been extended to include four new products including the solid dose oncology drug temozolomide and Accord's first biosimilar, Accofil® (filgrastim) for the treatment of chemotherapy-induced neutropenia (an abnormally low number of neutrophil white blood cells). For the first time, the agreement has been expanded to include drugs from additional therapeutic areas including diabetes (glimepiride) and transplant rejection (mycophenelate).

Clinigen CTS has partnered with Accord since 2012 to deliver its oncology products, including cisplatin, cytarabine, docetaxel, doxorubicin and fluorouracil, into clinical trials. The CTS team is the sole point of contact for all clinical trial supply enquiries, and distributes Accord's products to manufacturers, contract research organizations (CROs), clinical trial contract packagers and other specialist service providers. The drugs are supplied for use as comparator, co-therapy, rescue and adjunctive drugs in clinical trials.

Daniel Green, Regional Director UK & Ireland at Accord said: "We have been impressed with the service provided by Clinigen CTS since 2012 and are pleased to be able to continue and extend our exclusive agreement with an additional four new products. The partnership has enabled us to maximise the impact of our products in clinical trials which we see as an important area."

Steve Glass, Group Managing Director, Clinigen Group said: "Clinigen is committed to providing the best possible clinical trial service and distribution capabilities. This has been demonstrated by both the continuation of this strong partnership and Accord's decision to extend the agreement to include four more key products. We are pleased to be working with the Accord team for another two years." 

- Ends - 

About Clinigen Group

Clinigen Group is a global pharmaceutical and services company with a unique combination of businesses dedicated to delivering the right drug to the right patient at the right time.

The Group consists of four synergistic businesses that provide medicines to patients with unmet medical need; through Clinigen Clinical Trial Services we manage the supply of commercial medicines for clinical trials, through Idis Managed Access we run early access programs for our own and other companies' portfolios, our Idis Global Access team works directly with healthcare providers to enable ethical compliant access to unlicensed medicines, and through Clinigen Specialty Pharmaceuticals, we market our own portfolio of niche commercial products.

Clinigen is the global leader in clinical trial services and ethically sourcing and supplying unlicensed medicines to hospital pharmacists and physicians for patients with a high unmet need. In October 2015, Clinigen acquired Link Healthcare, further strengthening our international distribution network in the AAA region - Asia, Africa and Australasia.

For more information, please visit www.clinigengroup.com 

About Accord Healthcare Ltd

Accord Europe started commercial marketing activities in August 2008. Pan-European coverage has been rapidly attained and as of 2015 Accord products have been sold in over 30 European markets. Since the beginning of its commercial activities Accord has shipped over 200 million packs of pharmaceuticals (equating to over five billion doses) within Europe bringing benefit to millions of patients. To date Accord has gained nearly 5,000 product approvals across the European Economic Area and the company is actively working on extending this number, so more patients can benefit from our products in future.

Accord is committed to uncompromised quality for its products and services across the globe. Our products are manufactured under the highest international standards and our manufacturing plants are approved by major global regulatory agencies including the USFDA, MHRA, EMA, TGA, MCC, ANVISA. Increasingly Accord is investing in higher barrier to entry developments such as Biosimilar and New Chemical Entities and is set to evolve into a leading global healthcare provider. 

For more information visit www.accord-healthcare.eu

Contact Details